Superconducting Magnets Market to Grow at 0.88% CAGR During the Period 2017-2021
Category: #world  By Saipriya Iyer  Date: 2017-05-10
  • share
  • Twitter
  • Facebook
  • LinkedIn

Superconducting Magnets Market to Grow at 0.88% CAGR During the Period 2017-2021 global superconducting magnets market report that lists top companies as Siemens, Sumitomo Electric Industries, and Columbus Superconductors. Other Prominent Vendors in the market are: Agilent Technologies, American Magnetics, and Bruker. Commenting on the report, an analyst team said: ?One trend in market is partnerships between interventional MRI image guided systems and pharmacological companies. Partnership with pharmaceutical companies and clinical studies to check the efficacy of both MRI image guided system, and pharmacological products can improve the sales of products after the regulatory approval. It is a strategy used by the companies to compete with other companies, which can increase the sales of interventional MRI-guided systems by expanding the range of applications.? According to the report, one driver in market is more power required for smaller spaces. Superconducting materials are a paradigm shift in terms of offering a solution to the problems of efficiency and energy distribution. The increase in energy consumption and the densification of the urban areas is a serious electric utility problem. The superconductor's ability to transact high current densities is a highly compact technological alternative to conventional copper lines. Superconducting cables have a 10 times higher capacity compared to conventional cables carrying transmission-level power at distribution voltages. These features of superconductors are crucial when electricity is produced at a very long distance away from the places it is used. Superconducting cables have a much smaller footprint as compared to traditional distribution and transmission lines. Further, the report states that one challenges in market is limited demand for maglev trains. Japan has intense competition from France and China for high-speed rail transport. The country has not found any buyers for its maglev technology despite its aggressive marketing strategies. Japan has plans to build a high-speed maglev line from Tokyo to Osaka leading on to Nagoya. This construction of this segment in between Tokyo and Nagoya is expected to be completed by 2027 and costs $46 billion. The line to Osaka is expected to be connected by 2045 at an overall project cost of $76 billion. Train technology is dependent on magnetic power to float the cars above the ground preventing friction with the steel tracks. The trains start off by running on wheels and later, and when they pick up speed, the superconducting magnets take over and induce the lift. High construction costs and uncertain demands are the reason for resistance to plans for high-speed rails in the UK and the US. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.


About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Montero inks agreement to acquire Isabella Gold Silver Project
Montero inks agreement to acquire Isabella Gold Silver Project
By Saipriya Iyer

Montero Mining and Exploration Ltd. has reportedly inked a Binding Purchase & Sale Agreement to acquire a 100% or full interest in a private company in Chile. ChileCo holds several mineral rights to exploration cla...

PharmaCyte to submit IND application to FDA for clinical trial in LAPC
PharmaCyte to submit IND application to FDA for clinical trial in LAPC
By Saipriya Iyer

PharmaCyte Biotech, a clinical-stage biotechnology company, is reportedly set to submit an IND (Investigational New Drug) application to the U.S. FDA. The IND application is related to the Phase 2b clinical trial among...

Immunic announces topline data from Phase 2 EMPhASIS, IMU-838 trial
Immunic announces topline data from Phase 2 EMPhASIS, IMU-838 trial
By Saipriya Iyer

Immunic, Inc. has recently announced positive topline results from the Phase 2 EMPhASIS trial of IMU-838, in patients with RRMS (relapsing-remitting multiple sclerosis). IMU-838 is a next-generation, orally available s...